These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36902476)

  • 21. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
    Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
    Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
    Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
    Kalikaki A; Politaki H; Souglakos J; Apostolaki S; Papadimitraki E; Georgoulia N; Tzardi M; Mavroudis D; Georgoulias V; Voutsina A
    PLoS One; 2014; 9(8):e104902. PubMed ID: 25137394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
    Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
    Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
    Messaritakis I; Sfakianaki M; Papadaki C; Koulouridi A; Vardakis N; Koinis F; Hatzidaki D; Georgoulia N; Kladi A; Kotsakis A; Souglakos J; Georgoulias V
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):767-775. PubMed ID: 30094617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer.
    Otsuka K; Imai H; Soeda H; Komine K; Ishioka C; Shibata H
    Anticancer Res; 2013 Feb; 33(2):625-9. PubMed ID: 23393358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
    Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
    Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.
    Brechbuhl HM; Vinod-Paul K; Gillen AE; Kopin EG; Gibney K; Elias AD; Hayashi M; Sartorius CA; Kabos P
    Mol Carcinog; 2020 Oct; 59(10):1129-1139. PubMed ID: 32822091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques.
    Kaifi JT; Kunkel M; Das A; Harouaka RA; Dicker DT; Li G; Zhu J; Clawson GA; Yang Z; Reed MF; Gusani NJ; Kimchi ET; Staveley-O'Carroll KF; Zheng SY; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):699-708. PubMed ID: 25807199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma.
    Vismara M; Reduzzi C; Silvestri M; Murianni F; Lo Russo G; Fortunato O; Motta R; Lanzoni D; Giovinazzo F; Miodini P; Pasquali S; Suatoni P; Pastorino U; Roz L; Sozzi G; Cappelletti V; Bertolini G
    Clin Chem; 2022 May; 68(5):691-701. PubMed ID: 35304611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and
    El-Heliebi A; Hille C; Laxman N; Svedlund J; Haudum C; Ercan E; Kroneis T; Chen S; Smolle M; Rossmann C; Krzywkowski T; Ahlford A; Darai E; von Amsberg G; Alsdorf W; König F; Löhr M; de Kruijff I; Riethdorf S; Gorges TM; Pantel K; Bauernhofer T; Nilsson M; Sedlmayr P
    Clin Chem; 2018 Mar; 64(3):536-546. PubMed ID: 29301749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
    Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
    Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
    Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
    Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer.
    Brungs D; Lynch D; Luk AW; Minaei E; Ranson M; Aghmesheh M; Vine KL; Carolan M; Jaber M; de Souza P; Becker TM
    World J Gastroenterol; 2018 Feb; 24(7):810-818. PubMed ID: 29467551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biology and significance of circulating and disseminated tumour cells in colorectal cancer.
    Steinert G; Schölch S; Koch M; Weitz J
    Langenbecks Arch Surg; 2012 Apr; 397(4):535-42. PubMed ID: 22350614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection and clinical significance of circulating tumour cells in patients with colorectal carcinoma.
    Ihnát P; Srovnal J; Hrubovčák J; Martínek L
    Rozhl Chir; 2023; 102(10):376-380. PubMed ID: 38302423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
    Chikamatsu K; Tada H; Takahashi H; Kuwabara-Yokobori Y; Ishii H; Ida S; Shino M
    Oral Oncol; 2019 Feb; 89():34-39. PubMed ID: 30732956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.